{
    "organizations": [],
    "uuid": "316958e49e697816adc61eb52ec1bd2c86f877a7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-incyte-reports-q1-loss-of-019-per/brief-incyte-reports-q1-loss-of-0-19-per-share-idUSASC09YIO",
    "ord_in_thread": 0,
    "title": "BRIEF-Incyte Reports Q1 Loss Of $0.19 Per Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1 (Reuters) - Incyte Corp:\n* INCYTE REPORTS 2018 FIRST-QUARTER FINANCIAL RESULTS AND UPDATES ON KEY CLINICAL PROGRAMS\n* Q1 NON-GAAP LOSS PER SHARE $0.01\n* Q1 REVENUE $382 MILLION VERSUS I/B/E/S VIEW $389.7 MILLION\n* Q1 LOSS PER SHARE $0.19 * Q1 EARNINGS PER SHARE VIEW $0.01 — THOMSON REUTERS I/B/E/S\n* INTENDS TO CONTINUE TO INVESTIGATE EPACADOSTAT’S POTENTIAL AS A COMPONENT OF COMBINATION IMMUNOTHERAPY IN PROOF-OF-CONCEPT TRIALS\n* TWO TRIALS OF EPACADOSTAT IN COMBINATION WITH PEMBROLIZUMAB IN LUNG CANCER WILL BE CONVERTED INTO RANDOMIZED PHASE 2 TRIALS\n* SEES FY 2018 GAAP AND NON-GAAP JAKAFI NET PRODUCT REVENUES OF $1,350 MILLION - $1,400 MILLION\n* SEES FY 2018 GAAP AND NON-GAAP ICLUSIG NET PRODUCT REVENUES OF $80 MILLION - $85 MILLION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-01T19:27:00.000+03:00",
    "crawled": "2018-05-02T15:57:02.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "incyte",
        "corp",
        "incyte",
        "report",
        "financial",
        "result",
        "update",
        "key",
        "clinical",
        "program",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "intends",
        "continue",
        "investigate",
        "epacadostat",
        "potential",
        "component",
        "combination",
        "immunotherapy",
        "trial",
        "two",
        "trial",
        "epacadostat",
        "combination",
        "pembrolizumab",
        "lung",
        "cancer",
        "converted",
        "randomized",
        "phase",
        "trial",
        "see",
        "fy",
        "gaap",
        "jakafi",
        "net",
        "product",
        "revenue",
        "million",
        "million",
        "see",
        "fy",
        "gaap",
        "iclusig",
        "net",
        "product",
        "revenue",
        "million",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}